FDA Drugs recall ·
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL)… recall
- Recall number
- D-0251-2026
- Date
- (initiated December 18, 2025)
- Company / brand
- Imprimis NJOF, LLC
1705 Route 46 Ste 6B, Ledgewood, NJ, United States - Category
- Drugs › Class II
- Classification
- Class II
- Status
- Ongoing
- Units affected
- 314 boxes of 6,280 pre-filled syringes
- Initiated by
- Voluntary: Firm initiated
Read the official FDA notice ↗
Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Why was it recalled?
Presence of particulate matter - Glass like particles.
What should you do?
FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.
Product codes & lot numbers
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Distribution
U.S Nationwide
What does Class II mean?
Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
Source: FDA (drugs), recall D-0251-2026. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.